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The Moloney murine leukemia virus causes thymic leukemias when injected into newborn mice. A major
genetic determinant of the thymic disease specificity of the Moloney virus genetically maps to two protein
binding sites in the Moloney virus enhancer, the leukemia virus factor b site and the adjacent core site. Point
mutations introduced into either of these sites significantly shifts the disease specificity of the Moloney virus
from thymic leukemia to erythroleukemia (N. A. Speck, B. Renjifo, E. Golemis, T. Fredrickson, J. Hartley,
and N. Hopkins, Genes Dev. 4:233-242, 1990). We have purified several polypeptides that bind to the core site
in the Moloney virus enhancer. These proteins were purified from calf thymus nuclear extracts by selective pH
denaturation, followed by chromatography on heparin-Sepharose, nonspecific double-stranded DNA-cellulose,
and core oligonucleotide-coupled affinity columns. We have achieved > 13,000-fold purification of the
core-binding factors (CBFs), with an overall yield of approximately 19%. Analysis of purified protein fractions
by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis reveals more than 10 polypeptides. Each
of the polypeptides was recovered from an SDS-polyacrylamide gel, and those in the molecular size range of 19
to 35 kDa were demonstrated to have core-binding activity. The purified CBFs were shown by DNase I
footprint analyses to bind the core site in the Moloney virus enhancer specifically, and also to core motifs in the
enhancers from a simian immunodeficiency virus, the immunoglobulin ,. chain, and T-celi receptor y-chain
genes.

Although several DNA-binding proteins contribute to thymic disease specificity of the Moloney MLV, we and others
have been particularly interested in proteins that bind to the
core site. Both in vivo transcription analyses and genetic
studies indicate that the core site contributes more significantly than other protein binding sites to the T-cell transcriptional preference of the Moloney and SL3-3 MLV enhancers
and to the T-cell disease specificity of the Moloney virus (37,
50, 51). For example, several studies demonstrated that
point mutations in the core site in both the Moloney and
SL3-3 MLV enhancers attenuate transcription specifically in
hematopoietic cell lines (4, 38, 51, 55), whereas mutations in
the LVb site in the Moloney MLV enhancer attenuate
transcription in all cell types analyzed (51). Point mutations
in the core site of the Moloney virus enhancer also caused
the most dramatic shift in disease specificity of the virus,
resulting in a 65% incidence of erythroleukemia, compared
with the more modest 25% shift that occurred upon mutation
of the adjacent LVb site (50).
Several protein-DNA complexes have been identified in
T-cell nuclear extracts that bind to the core sequences in the
Moloney, SL3-3, and AKV MLV enhancers (4, 49, 55). One
of these protein-DNA complexes, variously called the SL3-3
and AKV core-binding factor (S/A-CBF) or the SL3-3 enhancer factor 1 (SEF1), binds to the slightly different core
sequences from all three of these viruses (4, 55). ProteinDNA complexes specific for the SL3-3 core site (S-CBF) and
AKV core site (A-CBF) have also been identified, and
S-CBF has been purified to near homogeneity (4, 34).
We have purified several polypeptides that bind the core
site in the Moloney MLV enhancer. We have named these
proteins simply core-binding factors (CBFs), since the proteins bind not only the core sites in the SL3-3 and AKV
MLV enhancers but also the core sites in the Moloney virus

Many replication-competent murine leukemia viruses
(MLVs) cause T-cell lymphomas and leukemias in newborn
mice and rats (60). A number of genetic studies have
identified the enhancer region of these viruses as an important determinant of both thymotropism and T-cell specificity
of transformation (6, 8, 9, 12-15, 28, 35, 36, 57). The MLVs
are thus an excellent model system for studying how viral
transcription influences viral tropism and pathogenesis.
The enhancers from several MLVs have been studied in
detail, with the goal of identifying host cell nuclear proteins
that bind to the enhancers and thereby influence the leukemogenicity and disease specificity of these viruses (37, 39,
49, 55). The MLV enhancers are often arranged as directly
repeated sequences, and, like all other viral enhancers
studied to date, they consist of a complex array of binding
sites for nuclear DNA-binding proteins (39, 49). Mutations
introduced into several of these binding sites in the enhancer
of the Moloney MLV reduced the incidence of thymic
leukemias caused by the Moloney virus, with a concurrent
appearance of erythroleukemias (Fig. 1A) (50). The binding
sites that appear to contribute to the thymic disease specificity of the Moloney virus include the leukemia virus factor
b (LVb) site and a conserved core motif that was originally
identified by Weiher et al. (59) in the enhancers from the
Moloney murine sarcoma virus, simian virus 40 (SV40), and
the mouse polyomavirus. Both the LVb and core sites are
highly conserved in the enhancers from mammalian C-type
retroviruses (21). In addition, mutation of 2 bp near the
leukemia virus factor c (LVc) site in the Moloney virus
enhancer also caused a significant alteration in disease
specificity (20). This latter sequence is not well conserved
among mammalian C-type viruses, and a protein that binds
to this site has not yet been identified.
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FIG. 1. Origins of oligonucleotides used to detect core-binding
activity. (A) A schematic representation of the Moloney MLV long
terminal repeat is shown at the top. The sequence at the bottom is
from the promoter-distal copy of the direct repeat of the Moloney
MLV enhancer (numbering is relative to the cap site at the 5' end of
the Moloney MLV viral genome [61]). Binding sites for nuclear
factors (leukemia virus factor a [LVa], nuclear factor I [NFl], LVb,
core, LVc, and glucocorticoid regulatory element [GRE]) are shown
in boxes (49). The point mutations in the LVb, core, and LVc
binding sites that altered the disease specificity of the Moloney virus
are shown above the sequence (20, 50). (B) Sequences of the top
strands of the 18-bp oligonucleotides used as probes and competitors in the electrophoretic mobility shift assay for core-binding
activity. The sequence differences between the MUT and HA
binding site versus the WT binding site are underlined.
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MATERIALS AND METHODS
Biochemical assays. (i) Wild-type, mutant, and high-affinity
substrates for protein binding in electrophoretic mobility shift

Complementary 18-base oligonucleotides containing
high-affinity (HA) core site, wild-type (WT) core site, and
mutant (MUT) core site (for sequences, see Fig. 1) were
synthesized on a Biosearch Cyclone DNA synthesizer at
Dartmouth Medical School and purified by electrophoresis
through 20% polyacrylamide-7 M urea gels.
Radioactive probes were made by end-labeling 100 pmol
of one oligonucleotide, either the top or bottom strand of the
binding site, with [-y-32P]ATP (7,000 Ci/mmol; ICN) and T4
polynucleotide kinase (New England Biolabs) and then
annealing the labeled oligonucleotide with 100 pmol of its
complementary strand (31). The double-stranded probes
were then purified by electrophoresis through a 20% native
polyacrylamide gel. The specific activity of the probes was
typically 4,000 to 10,000 cpm/fmol.
Competitor oligonucleotides were prepared by annealing
equal amounts of unlabeled complementary oligonucleotides. The annealed oligonucleotides were used directly as
competitors in binding reactions.
(ii) Substrates for methylation interference and DNase I
footprinting analyses. The probes used in methylation interference and DNase I footprinting analyses were prepared
from plasmid DNA. Two plasmids containing sequences
from the wild-type Moloney MLV enhancer (Pvu117938PvuI18013 and HaeII17949-HaeII17994, numbered [positions
indicated by subscripts] according to Weiss et al. [61],
subcloned into SP64) have been previously described (49).
Both the Pvu117938-Pvu118013 probe (fragment I) and the
assays.

a

by end labeling with [-y-32P]ATP in the presence of T4
polynucleotide kinase, either at the EcoRI or BamHI site in
the SP64 polylinker, and recutting at either BamHI or
EcoRI, respectively. A probe containing the Moloney MLV
enhancer with a mutated core site was prepared by subcloning the Pvu117938-Pvu118013 fragment from plasmid pMo
(core)CAT (51), which contains the Moloney MLV enhancer
with a 2-bp point mutation in the core site (CTGTGGTA
A-9CTGCCGTAA), into the SmaI site of pUC13. A probe
was prepared from this plasmid by cutting the pUC13
polylinker at either the EcoRI or BamHI site, end labeling,
and recutting at BamHI or EcoRI as described above.
The probe from the immunoglobulin >-chain enhancer was
obtained from plasmid p,uXDB (kindly provided by Ranjan
Sen), which contains an XbaI-to-DdeI fragment of the enhancer (nucleotides 1 to 521, according to Gillies et al. [19])
that was linkered with BamHI linkers and subcloned into the
BamHI site of SP64. The plasmid was cut and end labeled as
described above, either within the immunoglobulin >-chain
enhancer insert at Pvu11385 or in the XbaI site of the
polylinker of SP64, and recut at XbaI or PvuII to generate
the top- and bottom-strand probes for DNase I footprinting.
The T-cell receptor y-chain (TCR-y) enhancer probe was
prepared from plasmid J21-.20RR (52), kindly provided by
David Raulet. J21-.20RR contains a 196-bp RsaI-RsaI fragment from the TCR-y enhancer subcloned into the polylinker
of plasmid J21 (62). The plasmid was cut and end labeled in
the polylinker of J21 at either the XhoI or ClaI site and then
recut at ClaI or XhoI.
The probe from the simian immunodeficiency virus enhancer, clone 142 (SIVmacl42) (7), was prepared from
plasmid pSIV(-258)CAT, described by Renjifo et al. (45).
Plasmid pSIV(-258)CAT was cut and end labeled at the
Hindlll site in the polylinker or at the Rsal-71 site and then
recut at RsaI and HindIll, respectively.
All end-labeled probes were purified and eluted from 8 to
12% native polyacrylamide gels. Typical specific activities
were approximately 1,000 to 4,000 cpm/fmol of 5' ends.
(iii) Protein-DNA binding analysis. Core-binding activity
was detected by the formation of protein-DNA complexes in
the electrophoretic mobility shift assay (16, 18, 48). Typically, binding reaction mixtures contained 10,000 to 20,000
cpm (2 to 5 fmol) 32P-end-labeled probe, binding buffer (100
mM NaCI, 10 mM Tris (pH 7.4), 1 mM 3-mercaptoethanol,
1 mM EDTA, 4% glycerol), 0 to 1.0 ,ug of poly(dIdC) poly(dI-dC) (Pharmacia), and 1 to 10 RI of protein
sample, in a total volume of 15 [1I. To demonstrate the
sequence specificity of the protein-DNA complex, 50 ng
(500-fold molar excess) of unlabeled oligonucleotides was
included in some of the binding reaction mixtures. After 15
min of incubation at room temperature, the reaction mixtures were fractionated by electrophoresis through a 6%
native polyacrylamide gel in 0.5 x TBE (45 mM Tris-HCl, 45
mM boric acid, 1 mM EDTA) at room temperature. Radioactivity was detected by autoradiography of the dried gel.
The amount of DNA present in specific protein-DNA complexes was quantified by scintillation spectrometry of the
protein-DNA complex bands excised from dried polyacrylamide gels and counted in the presence of Ecoscint A
(National Diagnostics).
(iv) Protein assay. Protein concentrations were determined
by the method of Bradford (5), using reagents purchased
from Bio-Rad. Bovine serum albumin (BSA) was used as a
standard for determining the protein concentration.
(v) Measurement of NaCi concentration. The concentration
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of NaCI in column fractions was determined by measuring
conductivity in comparison with a standard curve.
(vi) SDS-PAGE. Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) was performed essentially
as described by Laemmli (33). For very dilute protein
samples (<100 jig/ml), 9.1% trichloroacetic acid (TCA) was
used to precipitate the proteins in the presence of deoxycholate (0.14 mg/ml) as carrier.
A modified procedure of silver staining (63) was used to
visualize the protein in the gel. Briefly, following electrophoresis, the gel was fixed with 50% methanol for 2 h, washed
with distilled water for 30 min, stained with a silver nitrate
solution (0.075% NaOH, 0.46% NH40H, 0.4% AgNO3) for
15 min, washed with distilled water for 15 min, and developed in a solution consisting of 0.005% citric acid and
0.035% formaldehyde. The staining was stopped by 50%
methanol. For Coomassie brilliant blue staining, the gel was
fixed for 15 min in 10% acetic acid-50% methanol and
stained for 1 h with 10% acetic acid-50% methanol-0.05%
Coomassie brilliant blue R-250 (Bio-Rad). The gel was
destained with 10% acetic acid.
(vii) Recovery and renaturation of protein from SDS-polyacrylamide gels. Denaturation/renaturation experiments
were performed essentially as described by Hager and
Burgess (23), with several modifications. Briefly, protein
samples were prepared and electrophoresed as described
above, and gels were stained with Coomassie brilliant blue.
Each of the visible polypeptide bands was excised from the
gel and chopped into small pieces. Proteins were eluted by
incubating the gel slice overnight at room temperature in 200
to 300 ,u of a buffer containing 150 mM NaCI, 20 mM
acid
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
(HEPES; pH 7.5), 5 mM dithiothreitol (DTT), 0.1 mM
EDTA, 0.1% SDS, and 0.1 mg of BSA per ml. The eluted
protein was precipitated with 4 volumes of cold (-20°C)
acetone and collected by centrifugation (16,000 x g for 30
min). The pellet was washed with a solution containing 80%
acetone and 20% dilution buffer (150 mM NaCl, 20 mM
HEPES [pH 7.5], 1 mM DTT, 0.1 mM EDTA, 20% glycerol),
dried, dissolved in 50 ,ul of dilution buffer supplemented with
6 M guanidine-HCI, and incubated at room temperature for
30 min. The protein was then renatured by dialysis on a
0.025-jim-pore-size filter disk (Millipore) (10) against 4 ml of
dilution buffer in one well of a 12-well microtiter plate for 1
h at room temperature. The protein samples were then
transferred to Eppendorf tubes and assayed for core-binding
activity by electrophoretic mobility shift assay.
(viii) Methylation interference analysis. The 45-bp
HaeIII7949-HaeIII7994 fragment from the Moloney MLV
enhancer was used as probe in methylation interference
analyses (25). The binding reaction (50 jil, total volume)
contained 100,000 cpm of end-labeled methylated (40) probe
and 25 pI of affinity-purified protein in the same buffer used
for electrophoretic mobility shift assays. The binding reaction was electrophoresed through a 5% native polyacrylamide gel. Following overnight exposure of the gel, the
bands corresponding to the protein-DNA complex and free
DNA were excised from the gel, and the DNA was purified
by electroelution onto NA45 membranes (Schleicher &
Schuell) as described by Baldwin (2), subjected to 1 M
piperidine cleavage, and analyzed by electrophoresis
through a 12% polyacrylamide-7 M urea sequencing gel.
(ix) DNase I footprint analyses. DNase I footprinting assays
(17) were performed by using probes derived from the
enhancers from Moloney MLV, the immunoglobulin ji-chain
gene, the TCR-y gene, and SIVmacl42. Binding reactions
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contained 2% polyvinyl alcohol, 0.8 mg of BSA per ml, 0.5 x
buffer Z (see below), 20,000 cpm of end-labeled probe, and
various amounts of affinity-purified CBF, in a total volume of
50 jil. The binding reaction mixtures were incubated on ice
for 1 h. The DNA was then digested with 25 mU of DNase I
(DPFF; Worthington Biochemicals) in the presence of 5 mM
CaCl2 for 1 min, at which point the reactions were terminated by the addition of 90 jil of DNase I stop buffer (20 mM
EDTA [pH 8.0], 1.0% SDS, 0.2 M NaCl, 250 jig of tRNA per
ml). The reaction mixture was extracted with phenol-chloroform, and the DNA was recovered by ethanol precipitation. The samples were electrophoresed through 8 to 10%
polyacrylamide-7 M urea sequencing gels along with chemical sequencing tracts (40).
Purification of CBF. (i) Buffers. Homogenization buffer
(buffer H) contains 250 mM sucrose, 50 mM HEPES (pH
7.5), 25 mM KCl, 10 mM 3-mercaptoethanol, 5 mM MgCl2,
and 1 mM phenylmethylsulfonyl fluoride (PMSF). Extract
buffer (buffer E) contains 250 mM sucrose, 400 mM NaCl, 50
mM HEPES (pH 7.5), 10 mM P-mercaptoethanol, and 1 mM
PMSF. Buffer B contains 50 mM NaCl, 20 mM HEPES (pH
7.5), 10 mM 3-mercaptoethanol, 2 mM EDTA, and 10%
glycerol. Buffer Z contains 100 mM NaCl, 25 mM HEPES
(pH 7.5), 1 mM DTT, 20% glycerol, 1 mM EDTA, and 0.1%
Nonidet P-40.
(ii) Preparation of the HA and WT core site affinity columns. Affinity resins were prepared by Kadonaga and
Tjian's modification of their original method (31). Complementary oligonucleotides with the following sequences were
used to prepare the affinity columns:

5'-ATATCTGTGGTAAGCGG-3'
3'-CGCCTATAGACACCATT-5'
HA: 5'-GGATATTTGCGGTTAGCA-3'
3'-TAAACGCCAATCGTCCTA-5'
WT:

Oligonucleotides were synthesized and purified as described
above. Each of the two complementary strands of either the
WT core site or HA core site (440 jig of each; 880 jig total)
was annealed, phosphorylated, concatenated, and coupled
to 5 ml of Sepharose CL-2B (Pharmacia), immediately
following activation of the resin with CNBr (Aldrich), as
described by Kadonaga and Tjian (31). The efficiency of
coupling was >90%.
(iii) Regeneration of chromatography resins. Heparin-Sepharose was regenerated according to the manufacturer (Pharmacia). Nonspecific calf thymus DNA-cellulose (Sigma) was
regenerated by washing with buffer B containing 2.5 M
NaCl. Affinity resins were regenerated as described by
Kadonaga and Tjian (31). The regenerated resins were all
equilibrated with 10 volumes of the appropriate running
buffers before samples were applied to the columns.
(iv) Preparation of nuclear extracts. Calf thymus was
obtained from newly slaughtered 16-week-old calves at a
slaughterhouse in Hyde Park, Vt. The thymuses either were
used directly after slaughter or were diced into approximately 1-cm cubes, snap frozen in liquid N2, and stored at
-80°C until needed. Frozen thymus was thawed in ice-cold
buffer H before homogenization.
All steps were performed at 4°C. Nuclei were prepared
from calf thymus essentially by the method of Halligan and
Desiderio (24). Four hundred grams (wet weight) of diced
calf thymus tissue was homogenized in a Waring blender
(two pulses of 30 s each at highest speed) in 1 liter of buffer
H. The crude lysate was passed through two, four, and eight
successive layers of cheesecloth to remove unblended ma-
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terial and connective tissue. The nuclei were collected by
centrifugation at 1,800 x g for 7 min in a GSA rotor. The
nuclear pellet was resuspended by hard shaking in 800 ml of
buffer E and incubated on ice for 15 min. Nuclei were then
pelleted by centrifugation at 12,000 x g in a GSA rotor for 10
min. Proteins in the supernatant were further precipitated by
slow addition of ammonium sulfate over 20 min with constant stirring to a final concentration of 50%, and the reaction
mixture was allowed to equilibrate with constant stirring for
an additional 30 min. The ammonium sulfate precipitate was
then collected by centrifugation at 16,000 x g for 45 min in
a GSA rotor. The pellet was resuspended in 100 ml of buffer
B and dialyzed twice against 2 liters of buffer B overnight. A
precipitate that formed during dialysis was removed by
centrifugation at 10,000 x g for 10 min in an SS34 rotor. The
supernatant from this centrifugation was designated the
nuclear extract. The protein concentration in the nuclear
extract was typically 25 to 30 mglml. Typical yields were 1 g
of nuclear extract per 100 g of calf thymus tissue.
(v) Selective pH denaturation of the nuclear extract. A pH
titration for the selective pH denaturation step was performed for each independent preparation of calf thymus
nuclear extract. Phosphoric acid (5 M) was used to lower the
pH of 15 ml of the nuclear extract. The pH of the nuclear
extract was titrated from pH 7.0 to 2.5, and 1-ml aliquots
were removed in increments of 0.5 pH units. The proteins
were allowed to precipitate overnight at4°C. Precipitated
proteins were removed by centrifugation at 16,000 x g for 10
min, and the pH of the supernatant was then readjusted to
7.0 by the addition of 14.8 M NH40H. Electrophoretic
mobility shift assays were used to determine the yield of
core-binding activity in each sample, and Bradford assays
were used to determine the protein concentration. Generally, pH 4.5 to 5.0 was found to be the optimal pH for this
step. For the purification summarized in Table 1, 130 ml of
nuclear extract (3,120 mg of protein) was selectively pH
denatured at pH 4.6.
(vi) Heparin-Sepharose chromatography. The supernatant
following pH denaturation was applied directly onto a heparin-Sepharose column (2.5 by 8.1 cm, 40 ml) that was
equilibrated with buffer B. The column was washed with 3
column volumes of buffer B, and the core-binding activity
was eluted with a 400-ml linear gradient of NaCl from 50 mM
to 1.0 M in buffer B, and approximately 5-ml fractions were
collected. Fractions were analyzed for core-binding activity,
protein concentration, and NaCl concentration. Fractions
with core-binding activity were pooled and dialyzed against
buffer B.
(vii) Nonspecific DNA-cellulose chromatography. Dialyzed
pooled fractions from the heparin-Sepharose column were
applied to a nonspecific double-stranded DNA-cellulose
column (2.5 by 4.0 cm, 20 ml) that was equilibrated with
buffer B supplemented with 5 mM EDTA. The column was
washed with 3 column volumes of buffer B (plus 5 mM
EDTA) and developed with a 200-ml linear gradient of NaCl
from 50 mM to 1.0 M in buffer B plus 5 mM EDTA, and

approximately 4-ml fractions were collected.

Fractions

con-

taining specific core-binding activity were pooled and dialyzed against buffer Z.
(viii) Recognition site affinity chromatography. The HA
core site and WT core site DNA affinity columns (1 ml of
resin) were equilibrated with buffer Z. Pooled fractions from
the nonspecific DNA-cellulose column were adsorbed to
either the HA core site affinity column or the WT core site
affinity column. The column was washed with 10 column
volumes of buffer Z, and the core-binding activity was step
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FIG. 2. Effect of pH denaturation on core-binding activity. Electrophoretic mobility shift assay to detect core-binding activity
following selective pH denaturation. Phosphoric acid was used to
lower the pH of the nuclear extract from 7.0 to 2.5 in increments of
0.5 pH units as described in Materials and Methods. Each binding
reaction mixture contained 20,000 cpm of 32P-end-labeled WT
probe, ,1 ug of poly(dI-dC) poly(dI-dC), and 10 of a 1:10 dilution
of nuclear extract following pH denaturation, in the absence (-) or
presence of 50 ng (500-fold molar excess) of the WT or MUT
competitor oligonucleotide.

eluted either with 0.3 and 1.0 M NaCl in buffer Z for the HA
core site affinity column or with 0.3 and 0.6 M NaCI for the
WT core site affinity column. Fractions with core-binding
activity were pooled and dialyzed against buffer Z, and the
column was regenerated. The dialyzed sample was then
loaded again onto the same regenerated column and eluted
as described above. This procedure was repeated two additional times, for a total of four successive passages on either
the HA or WT core site affinity column.
RESULTS
Assay for core-binding activity. Core-binding activity was
detected by electrophoretic mobility shift assays (16, 18, 48).
The sequences of the three oligonucleotides that were used
as probes or competitors are shown in Fig. 1. Two different
probes were used in the electrophoretic mobility shift assay.
The first probe is a synthetic 18-bp oligonucleotide that
contains the WT core site from the Moloney virus enhancer.
The second probe is a deduced HA core sequence (56) with
greater binding affinity for CBF (data not shown). The
protein-DNA complex obtained with the Moloney virus WT
probe can be competed for by the unlabeled HA binding site
(data not shown). Likewise, the protein-DNA complex obtained with the HA probe can be competed for with the WT
binding site (data not shown). Therefore, the same proteins
appear to bind both the WT and HA probes. This is
consistent with the original results reported by Thornell et
al. (56) for the binding specificity of the analogous protein
that they call SEF1 to the core site from the SL3-3 virus
enhancer and the deduced core site.
The WT and HA probes have been used interchangeably
in the electrophoretic mobility shift assay throughout the
purification. We performed competition assays on active
fractions in each step of the purification with unlabeled WT
and HA oligonucleotides, and also with the MUT binding
site which contains the 2-bp mutation in the Moloney virus
core site that alters the disease specificity of the Moloney
virus from thymic to erythroid leukemia (50).
Purification of CBF. We purified the CBFs from calf
thymus nuclei by a combination of conventional chromatog-
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FIG. 3. Fractionation of CBF. (A and B) Chromatography on heparin-Sepharose. Nuclear extract was denatured to pH 4.6 as described
in Materials and Methods. The supernatant from the selective pH denaturation step was then loaded onto a 40-ml heparin-Sepharose column
equilibrated in buffer B (50 mM NaCI). The column was developed with a linear gradient of NaCl from 50 mM to 1.0 M. (A) An aliquot (5
p.1) of each 5-ml fraction was assayed for core-binding activity by mobility shift assay, using the WT probe (10,000 cpm per reaction), in the
presence of 200 ng of poly(dI-dC) poly(dI-dC). The amount of radioactivity (0) in the active fractions was quantified by scintillation
fluorography. The protein concentration (0) was determined by Bradford assay. (Inset) Conductivity measurement of the concentration of
NaCl in column fractions across the gradient. (B) Autoradiograph showing the DNA-binding activity in the active fractions. Lanes: Load, 1
,u1 of the loaded fraction; FT, 5 RIl of flowthrough fractions; 80 to 110, 5 [L1 of eluate fractions from the heparin-Sepharose column. (C and D)
Chromatography on the nonspecific DNA-cellulose column. Pooled fractions (87 to 107) from the heparin-Sepharose column were dialyzed
against buffer B and loaded on a 20-ml double-stranded calf thymus DNA-cellulose column in buffer B (supplemented with 5 mM EDTA). The
column was washed and developed with a linear gradient of NaCl from 50 mM to 1.0 M in buffer B (5 mM EDTA). (C) An aliquot (5 ,ul) of
each 2-ml fraction was assayed for specific DNA-binding activity (0) in the presence of 50 ng of poly(dI-dC) poly(dI-dC) and for protein
concentration (0) as described above. (Inset) Conductivity measurement of the concentration of NaCl in each column fraction. (D)
Autoradiograph showing the core-binding activity in the active fractions. Lanes: Load, 5 ,u1 of loaded pooled heparin-Sepharose column
fractions; FT, 5 ,ul of the flowthrough fractions; 62 to 78, elution fractions from the nonspecific DNA-cellulose column.

raphy and recognition site affinity chromatography (31, 46).
Calf thymus is an excellent source of CBF because it is
inexpensive, available in unlimited supply, and an enriched
source of T cells. Furthermore, thymus is the target organ
for leukemia induced by the Moloney virus.
In the course of our studies, we found that the corebinding activity is relatively stable at low pH. We therefore
exploited this property of CBF and used selective pH
denaturation as the initial purification step. We first determined the optimal pH with which the greatest purification of
CBF was obtained with an acceptable yield of activity. The
pH of the calf thymus nuclear extract was titrated from pH
7.0 to 2.5 in increments of 0.5 pH units, the extract was
centrifuged to remove the denatured precipitated proteins,
the supernatant was adjusted to pH 7.0, and the extract was
assayed for protein concentration and core-binding activity
(Fig. 2).
The DNA-binding activity that remains following selective
pH denaturation is specific for the core sequence, as shown

by the ability of a 500-fold molar excess of the WT but not
the MUT core site to compete for binding to the WT probe
(Fig. 2). The mobility of the protein-DNA complex increases
slightly as the pH is lowered, possibly as a result of partial
proteolysis of the proteins by activated acid proteases. The
protein-DNA complex is relatively wide; inclusion of less
core-binding activity in the binding reaction mixtures (or
shorter exposures of the mobility shift gels) reveals that this
large complex is composed of multiple protein-DNA complexes with different mobilities (data not shown).
The yield and purification of CBF following selective pH
denaturation varied somewhat between different preparations of nuclear extracts; therefore, an independent pH
titration was performed for each nuclear extract that was
used in the purification. In each of the independent CBF
purifications, pH denaturation was performed at either pH
4.6 or 5.0, depending on the starting material, and we
obtained a three- to sevenfold purification in this first step.
Following the selective pH denaturation, the supernatant
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TABLE 1. Purification of CBF'
Fraction

Protein (mg)b

Total activity (U)'

I. Nuclear extractd
II. pH denaturation
III. Heparin-Sepharose
IV. DNA-cellulose
V. Core affinity columne

3,120
556.5
131.6
5.2
0.044

312,000

100

191,300
124,000
62,000
58,900

344
942
12,020
1,338,640

Sp act (U/mg)

Total yield (%)

(fold)

100

61.3
39.8
20.0
19.0

3.4
9.4
120
13,386

a Data represent a single preparation of CBF, starting with 300 g (wet weight) of calf thymus.
b Protein was measured by the method of Bradford (5) for fractions I to
IV, using BSA as a standard. Protein concentration in fraction V was roughly estimated
from silver-stained SDS-polyacrylamide gels by adding together the amount of protein in individual polypeptide bands.
c One unit of activity is defined as the amount of binding by 10 ,ug of the nuclear extract. Binding was quantified by excising the protein-DNA complex from
the dried polyacrylamide gel and determining the amount of radioactivity in the protein-DNA complex by scintillation fluorography. Each reaction mixture
contained approximately 2 to 5 fmol of 32P-end-labeled oligonucleotide probe.
d Represents a 0 to 50% (NH4)2SO4 precipitate of proteins extracted in 400 mM NaCl from calf thymus nuclei (see Materials and Methods).
e Affinity chromatography was performed by using the HA core site affinity column. Data represent the fourth passage on the affinity column.

after centrifugation was chromatographed on a heparinSepharose column (Fig. 3A and B). Core-binding activity
eluted from the heparin-Sepharose column in a broad peak
between 400 and 600 mM NaCl and was shown to be specific
for the core sequence by competition assays (competition
data not shown). Pooled fractions from heparin-Sepharose
column with core-binding activity were subsequently chromatographed on a nonspecific double-stranded DNA-cellulose column (Fig. 3C and D). Core-binding activity eluted
from the DNA-cellulose column between 390 and 610 mM
NaCl. Additional activity eluted from the DNA-cellulose
column in 150 to 390 mM NaCl, coinciding with the major
protein peak, but this activity was not specific for the core
sequence (competition data not shown). We achieved an
approximately 3-fold purification of CBF on heparin-Sepharose and a 13-fold purification on the DNA-cellulose column,
resulting in an overall purification of 120-fold at this step
(Table 1).
Active fractions from the nonspecific DNA-cellulose column were further purified by recognition site affinity chromatography (31) on columns that were prepared with either
catenated WT or HA core binding sites (Fig. 4). Pooled
fractions containing core-binding activity from the first adsorption on the affinity column were dialyzed and readsorbed three additional times on the regenerated column.
The HA core site affinity column was developed with two
successive step elutions of 300 mM and 1 M NaCI. Corebinding activity did not elute from the HA site matrix in 300
mM NaCl, whereas >90% of core-binding activity was
recovered in the 1.0 M NaCI eluate (Fig. 4A). Inclusion of an
intermediate NaCl wash (600 mM NaCI) split the corebinding activity into two fractions: one that eluted from the
HA core site column in 600 mM NaCl, and a second fraction
that eluted in 1.0 M NaCl (data not shown).
Adsorption on the WT core site affinity column resulted in
a different elution profile, in that a significant proportion of
the core-binding activity eluted from the WT core site
column in 300 mM NaCl and the remaining core-binding
activity eluted from the column in 600 mM NaCl (Fig. 4B).
We also note that the proteins that preferentially elute from
the WT core site column in 300 mM NaCI give rise to
protein-DNA complexes that migrate faster on native polyacrylamide gels than do the protein-DNA complexes obtained with the 600 mM NaCl eluate.
We estimate that a >100-fold purification of CBF was
obtained from four successive passages on either the WT or
HA core site column, with 95% yield of core-binding activity
in this step. The purification of CBF is summarized in Table

1. Cumulatively, we have achieved a >13,000-fold purification of CBF, with an overall yield of 19%.
Analysis of CBF by SDS-PAGE. We performed three
independent purifications of CBF and analyzed affinitypurified fractions from each purification by SDS-PAGE (33).
Figure 5A shows the SDS-PAGE analysis of protein samples
from each step of one CBF purification. The HA core site
column was used in the final step of this particular preparation of CBF. Multiple polypeptides ranging in molecular size
from approximately 19 to 40 kDa were detected on the
SDS-polyacrylamide gel (Fig. SA, lane 5). The two polypeptides of approximately 60 kDa are keratin proteins, since
they are also present in lanes 6 and 7, which contain only
precipitated buffer and sample buffer, respectively. We had
anticipated that there would be multiple polypeptides in the
affinity-purified fractions, since this was consistent with the
observation that there are multiple protein-DNA complexes
on native polyacrylamide gels, and also that the core-binding
activity could be split into two fractions by elution in
different NaCl concentrations from affinity columns.
The second preparation of CBF was also purified on the
HA core site column. Multiple polypeptides in the affinity
purified fractions were again detected by SDS-PAGE, but
the pattern of polypeptides was not identical to that obtained
in the first purification (Fig. SB, lanes 3 and 4). Although
there are polypeptides common to affinity-purified CBF from
both preparations, there are also a number of polypeptides in
the first preparation of CBF (lane 4) that are either absent or
insufficiently abundant to be detected in the second CBF
preparation (lane 3).
In the third purification of CBF, the pooled fractions with
core-binding activity from the nonspecific DNA-cellulose
column were divided into two aliquots, and each of these
aliquots was independently purified by recognition site affinity chromatography. One aliquot of the pooled DNAcellulose eluate was chromatographed on the HA core site
affinity column, and the second aliquot was chromatographed on the WT core site column. A sample of the 1.0 M
NaCl eluate from the HA core site column was electrophoresed through lane 5 (Fig. SB) of the SDS-polyacrylamide gel, and the 300 and 600 mM NaCl eluates from the
WT core site column were electrophoresed through lanes 6
and 7, respectively. There is clearly variability in the number
and abundance of polypeptides between independent preparations of CBF. Note, however, that several polypeptides
consistently appear in every preparation of CBF. For example, a doublet that migrates at 42 kDa is in every CBF
preparation, as is a doublet that migrates just below the
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FIG. 4. Electrophoretic mobility shift assays of the core-binding
activity following affinity chromatography. (A) Affinity chromatography on the HA core site column. The autoradiograph shows
core-binding activity in eluate fractions from the fourth passage on
the HA core site affinity column. Pooled active DNA-cellulose
fractions (62 to 77) were dialyzed against buffer Z (0.1 M NaCl) and
adsorbed onto an affinity column containing 1 ml of the HA core site
affinity resin. The column was then washed with buffer Z (0.1 M
NaCl) and step eluted with buffer Z containing 0.3 and 1.0 M NaCl.
Binding reaction mixtures contained 5 pul of eluate fractions and
10,000 cpm of HA probe in a total volume of 15 jil. Lanes: Load,
loaded material; FT, flowthrough fractions; 0.1 M NaCl, 0.1 M NaCl
eluate; 42 to 60, 0.3 M NaCl eluate fractions; 62 to 78, fractions
eluted with 1.0 M NaCl. (B) Affinity chromatography on the WT
core site column. The active DNA-cellulose fractions were adsorbed
onto and eluted from the WT column four times successively as
described for panel A except that 0.3 and 0.6 M NaCl were used to
step elute the core-binding activity. Shown is the assay of fractions
from the fourth adsorption on the WT affinity column. Lanes: Load,
loaded material; FT, flowthrough fractions; 0.1 M NaCl, 0.1 M NaCl
eluate; 62 to 82, fractions eluted with 0.3 M NaCl; 84 to 94, fractions
eluted with 0.6 M NaCl.

31-kDa size marker, another doublet at 25.5 kDa, and a
single band at 22.5 kDa (Fig. 5B, arrows).
Denaturation/renaturation analysis of CBF. To determine
which of the multiple polypeptides that were seen by SDSPAGE possessed core-binding activity, we excised each
protein band that was visible from a Coomassie brilliant
blue-stained SDS-polyacrylamide gel, eluted the proteins
from each gel slice, and subjected the proteins to a denaturation/renaturation regimen described by Hager and Burgess
(23). Each of the renatured proteins was then assayed for

--

22
1 4

1 2 3 4 5 6 7 8
FIG. 5. Characterization of CBF by SDS-PAGE. (A) SDSPAGE analysis of fractions from one purification of CBF. Seven
micrograms each of crude extract, pH-denatured extract, and heparin-Sepharose activity pool were mixed with SDS sample buffer.
Protein samples from active pooled fractions from the nonspecific
DNA-cellulose and affinity columns were first concentrated by TCA
precipitation. Protein samples were electrophoresed through a 15%
SDS-polyacrylamide gel and visualized by silver staining. Lanes: 1,
7 ,ug of nuclear extract; 2, 7 ,ug of pH-denatured nuclear extract (pH
4.6); 3, 7 p.g of pooled heparin-Sepharose fractions; 4, 100 p.l of
pooled DNA-cellulose fraction; 5, 250 ,ul of pooled HA core site
affinity column fractions; 6 and 7, buffer Z and SDS sample buffer,
respectively; 8, low-molecular-weight markers (positions indicated
in kilodaltons). The two bands that migrate with an apparent
molecular mass of 60 to 66 kDa in the affinity-purified CBF fraction
(lane 5) are keratin proteins and are also present in control buffers
(lanes 6 and 7). (B) Affinity-purified fractions from several independent purifications of CBF, starting with different calf thymus nuclear
extracts. Eluate fractions from the HA and WT core site affinity
columns (500 pu) were TCA precipitated and electrophoresed
through a 15% SDS-polyacrylamide gel, and the gel was stained with
silver. Lanes: 1, buffer Z; 2, SDS sample buffer; 3 to 5, three

independent purifications of CBF eluted from the HA core site
affinity column in 1.0 M NaCl (lane 4 is from the first, lane 3 is from
the second, and lane 5 is from the third CBF purification); 6 and 7,
0.3 and 0.6 M NaCl eluates of CBF from the WT core site affinity
column, respectively; 8, low-molecular-weight markers (positions
indicated in kilodaltons). Arrows designate polypeptides that are
common to all CBF preparations. The samples in lanes 5 to 7 are
derived from one purification starting with the same calf thymus
nuclear extract and divided only at the affinity chromatography step.

core-binding activity by electrophoretic mobility shift assay
(Fig. 6).
Some of the polypeptide bands in the Coomassie brilliant
blue-stained SDS-polyacrylamide gel were very faint; they
cannot be easily seen in the photograph but could be seen by
the naked eye on the stained gel (Fig. 6A). The arrows to the
right of each lane in Fig. 6A mark the position of each
polypeptide that was excised from the gel. The keratin
proteins (the two uppermost proteins in each lane) were also
excised and used as negative controls. The polypeptides
were labeled alphabetically, from top to bottom of each lane
(largest to smallest). The letters assigned to each polypeptide
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FIG. 6. Renaturation of core-binding activity from SDS-polyacrylamide gels. (A) Fractionation of polypeptides by SDS-PAGE. Shown is
the Coomassie brilliant blue-stained SDS-polyacrylamide gel from which the different polypeptides were excised. CBF preparations are the
same as those shown in lanes 4 to 7 in Fig. SB. One milliliter of each affinity-purified fraction was TCA precipitated and electrophoresed
through a 15% SDS-polyacrylamide gel, and the gel was stained with Coomassie brilliant blue. Lanes: 1 and 4, proteins eluted from the HA
core site column from two independent purifications (corresponding to lanes 4 and 5 in Fig. 5B); 2 and 3, 0.3 and 0.6 M NaCl eluates from
the WT core site affinity column (corresponding to lanes 6 and 7 in Fig. SB); L, low-molecular-weight markers (positions indicated in
kilodaltons). Arrows indicate the bands that were excised from the Coomassie brilliant blue-stained SDS-polyacrylamide gel. These bands
were labeled sequentially by letters from top to bottom (1A to 1H, 2A to 2G, 3A to 3N, and 4A to 4K). The two keratin proteins (top two
bands, A and B in each lane) were also excised from each lane and used as negative controls for core-binding activity. The doublet migrating
at approximately 42 kDa (large and small arrows) was excised in a single gel slice (polypeptide C). (B) Electrophoretic mobility shift assay
of core-binding activity from renatured polypeptides. The excised polypeptides were eluted from the SDS-polyacrylamide gel slices and
subjected to a denaturation/renaturation regimen as described in Materials and Methods. Ten microliters of each renatured protein was
assayed for core-binding activity, using 10,000 cpm of the HA probe, in the absence of poly(dI-dC) poly(dI-dC). The number in each lane
corresponds to the lanes 1 to 4 from the SDS-polyacrylamide gel shown in panel A. The letter corresponds to the individual polypeptides (A
to N) marked by arrows from top to bottom in each lane in the SDS-polyacrylamide gel (i.e., 1A corresponds to the top polypeptide A excised
from lane 1 in the Coomassie brilliant blue-stained SDS-polyacrylamide gel in panel A). Samples numbered 1 to 4 represent 5 Fil of each
affinity-purified CBF sample prior to fractionation by SDS-PAGE. (C) Sequence specificity of the renatured polypeptides. Ten microliters of
each of the renatured polypeptides was assayed, using the HA probe as described for panel B, in the absence (-) or presence of the HA or
MUT competitor.

do not necessarily correspond to the same polypeptide in
each lane (e.g., polypeptide 1E in lane 1, which is the
fifth-largest polypeptide in this sample, is not equivalent to
polypeptide 2E, the fifth-largest polypeptide in lane 2). In
each lane, however, the two keratin proteins were the two
largest proteins and thus are labeled A and B in each sample.

All of the polypeptides that were recovered from the
SDS-polyacrylamide gel, in the size range of 19 to 35 kDa,
had core-binding activity (Fig. 6B). These correspond to
polypeptides 1D to 1H, 2D to 2G, 3D to 3N, and 4D to 4K in
the mobility shift assay. Neither of the keratin proteins
(polypeptides A and B in each lane) had core-binding activ-

VOL. 12, 1992

PURIFICATION OF MURINE LEUKEMIA VIRUS ENHANCER CBF

ity. Polypeptide C, which is the third-largest polypeptide in
each sample and migrates as a doublet at 42 kDa (large and
small arrows), also had no core-binding activity in all but one
sample (lane 1 from Fig. 6A; polypeptide 1C in Fig. 6C). We
suspect that the 42-kDa doublet comigrates with a polypeptide with core-binding activity that was present in this
particular CBF preparation. The remainder of the polypeptides (1D to 1H, 2D to 2G, 3D to 3N, and 4D to 4K) bind the
core site. The mobility of the protein-DNA complexes
increased with decreasing molecular weight of the renatured
proteins, and the distance between complexes with the
lowest and highest mobilities is approximately equivalent to
the width of the protein-DNA complex before fractionation
by SDS-PAGE (compare, for example, lanes 4D to 4K with
lane 4). We also note that many polypeptides gave rise to
two protein-DNA complexes with different mobilities. We
suspect that the larger, lower-mobility protein-DNA complex results from binding of two molecules of CBF to the
oligonucleotide probe. Competition assays established that
each of the polypeptides with DNA-binding activity binds
specifically to the core site (Fig. 6C).
Characterization of CBF binding sites. A methylation interference assay (25) was conducted to identify the purines
in the core site that are contacted by CBF (Fig. 7). Dimethylsulfate methylates guanine at the N-7 position, which
projects into the major groove. Methylation of three guanines on the top strand within the conserved core motif
(CTiTGGTAA) interferes with protein-DNA complex formation (asterisks in lane C [protein-DNA complex]). In
addition, we note that methylation at three adenines in the
minor groove (arrows) also interferes with CBF binding,
either by modifying the binding site for CBF or by distorting
the DNA helix in the minor groove.
We also performed DNase I footprinting analyses (17) to
confirm that CBF binds to the core site on the intact
Moloney virus enhancer. The DNase I footprint generated
by CBF is located directly over the core site in the 75-bp
repeat of the Moloney MLV enhancer (Fig. 8A and B).
Mutations in the core site that altered the thymic disease
specificity of the Moloney virus to erythroleukemia
(CTGTGTAA -* CTGCCGTAA) significantly disrupt the
binding of CBF to the Moloney MLV enhancer (Fig. 8C and
D). There appears to be only one binding site for CBF in one
copy of the Moloney virus direct repeat and thus presumably
two sites in the intact enhancer. We have not assayed for
CBF binding sites in the long terminal repeat outside of the
direct repeat region.
Core consensus sequences have been identified in a large
number of viral and cellular enhancers (19, 21, 52, 56, 59).
We analyzed several enhancers by DNase I footprinting to
determine which of these core motifs are bona fide binding
sites for CBF (Fig. 9). CBF binds three core sites in the
enhancer from the immunoglobulin ,u-chain gene and two
core sites in the enhancer from the TCR-y gene (Fig. 9A and
B). The core sites in the immunoglobulin ,u-chain gene were
originally identified by Gillies et al. (19) and were later
shown not to contribute to the transcriptional activity of the
immunoglobulin ,u-chain enhancer in B cells (30). The contribution of these core sites to transcription from the immunoglobulin ,u-chain enhancer in T cells has not been determined. The core sites in the TCRy gene are within a 200-bp
minimal enhancer fragment shown by Spencer et al. (52) to
be necessary for transcription in T cells.
CBF also binds one core site located between nucleotides
-147 to -165 in the enhancer from SIVmacl42 (Fig. 9C).
This core site is located in a region of the SIVmacl42
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FIG. 7. Methylation interference analysis of CBF on the Moloney MLV enhancer. (A and B) CBF was purified from an HA affinity
column as described in the legend to Fig. 4. SDS-PAGE analysis of
the CBF preparation used in the methylation interference analysis is
shown in Fig. 5B, lane 5. The probe used in the reaction contains a
45-bp HaeII-HaeIII fragment from the Moloney MLV enhancer
(nucleotides 7949 to 7994). A typical preparative reaction mixture
contained 100,000 cpm of probe in a final volume of 50 ,ul, with 25 ,ul
of affinity-purified CBF. (A) Top strand of the Moloney enhancer;
(B) bottom strand. Lanes C and F correspond to the protein-DNA
complex and free DNA bands, respectively. Asterisks indicate the
locations of guanines whose methylation specifically inhibits the
binding of CBF to the core site. Arrows indicate methylated
adenines that interfered with CBF binding. (C) Summary of methylation interference results. 0, guanine contacts; 0, adenines that
when methylated interfere with CBF binding.

enhancer that was demonstrated by 5' deletion analysis to
contribute to transcription of the enhancer in Rat-1 fibroblasts and to transcriptional stimulation by activators of
protein kinase C in Jurkat T cells (45). A binding site for CBF
is also present in the U3 region of the human immunodeficiency virus, at positions -391 to -408 relative to the
transcriptional start site (42) (data not shown).
We also performed DNase I footprinting assays on the
enhancer from the SV40 virus, which contains two core

motifs, GT-I and GT-IIC. CBF did not protect either the
GT-I or GT-IIC motif from DNase I digestion (data not
shown). Thornell et al. (55) also found that the binding of the
protein that they call SEF1 to the SL3-3 MLV core site could
not be competed for by a 50-fold molar excess of either the
GT-I or GT-IIC motif from the SV40 enhancer.
Figure 10 is a summary of the methylation interference
and DNase I footprinting analyses presented in Fig. 7 to 9.
DISCUSSION
We have purified several polypeptides from calf thymus
nuclei that bind the core site in the Moloney MLV enhancer.
Analysis of affinity-purified CBF preparations by SDS-
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FIG. 8. Binding of CBF to the Moloney MLV enhancer. (A) Binding to the top strand of the Moloney virus enhancer. The Moloney MLV
enhancer probe contains one copy of the 75-bp repeat of the enhancer, from Pvu117938 to Pvu118013. Each reaction mixture contained 10,000
cpm of end-labeled probe, 20 FLg of BSA, and various amounts of CBF purified on the HA core site column. The SDS-PAGE analysis of the
CBF preparation used in all DNase I footprinting analyses is shown in lane 5 of Fig. 5B. DNase I was added to the binding reaction mixture,
and the partially cleaved Moloney MLV enhancer fragment was electrophoresed through a 10% polyacrylamide-7 M urea sequencing gel.
Numbers above the lanes (0, 1, 5, and 10) represent the amounts (in microliters) of affinity-purified CBF added to the binding reaction mixture.
G, A, T, and C represent chemical sequencing tracks. Boxes at the left of the sequence indicate the position of the core motif (CTGTGGTAA)
in the Moloney MLV enhancer. (B) Binding of CBF to the bottom strand of the Moloney MLV enhancer. (C) Binding of CBF to the top strand
of the PvuII7938-Pvu118013 fragment from the Moloney MLV enhancer, containing the 2-bp mutation in the core site (CTGCCGTAA) that
altered the disease specificity of the Moloney virus (50). (D) Binding of CBF to the bottom strand of Moloney MLV enhancer with mutations
in the core site.

PAGE and denaturation/renaturation experiments reveals
more than 10 polypeptides that have core-binding activity.
There are several potential sources of the multiple polypeptides in affinity-purified preparations of CBF. One possible
explanation is that CBF is a family of transcription factors.
These proteins could be encoded by different genes, as in the
case of the octamer-binding proteins (27) or the AP-1 family
of transcription factors (11). Alternatively, the different
CBFs could result from multiple splicing of RNA transcribed
from a single gene, as in the case of the family of CCAAT
-box-binding proteins (CTF/NF1) (47) or the immunoglobulin transcription factors E2-5, E12, and E47 (26, 43).
Another explanation is that the multiple polypeptides
represent proteolytic cleavage products of a single CBF
precursor. We believe that proteolysis is a contributing
factor to the multiplicity of polypeptides for several reasons.
First, the heterogeneity in the composition of CBF preparations with respect to the number and abundance of polypep-

tides is suggestive of proteolytic cleavage that is occurring to
variable extents from one purification to the next. Second,
only the irreversible serine protease inhibitor PMSF was
used in preparing nuclear extracts, and extracts were often
made from previously frozen thymus tissue. When instead
we used calf thymuses obtained within 10 min of slaughter
and added a cocktail of protease inhibitors to the cell lysis
buffer (PMSF [10-' MI, pepstatin A [2.5 ,ug/ml], leupeptin [5
,ug/ml], aprotinin [12 ,ug/ml], SBTI [soybean trypsin inhibitor] [12 ,ug/ml], benzamidine [0.5 mg/ml], and E64 [5 mM]),
we could detect several larger polypeptides in the affinitypurified CBF preparations by SDS-PAGE, in addition to the
polypeptides seen in previous CBF preparations (data not
shown). These larger polypeptides ranged in molecular mass
from 32 to 41 kDa and also had core-binding activity, as
determined by denaturation/renaturation analysis (data not
shown). These two observations, the heterogeneity of polypeptides in different CBF preparations and the appearance of
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FIG. 9. Binding of CBF to the enhancers from the immunoglobulin ,u-chain and TCRy genes and from SIVmacl42. (A) Binding to the core
sites on the top and bottom strands of the immunoglobulin ,-chain enhancer. The immunoglobulin ,u-chain enhancer probe contains a 136-bp
sequence from Pvu11385 to Dde1521 (numbering according to Gillies et al. [19]), encompassing the three core sites identified by Gillies et al.
(19). Samples were electrophoresed through an 8% polyacrylamide-7 M urea sequencing gel. Assay conditions and symbols are the same as
in Fig. 8. (B) Binding of CBF to the top and bottom strands of the TCRy enhancer. The TCRy enhancer probe contains a 1%-bp restriction
fragment (nucleotides 284 to 480, numbered according to Spencer et al. [52]). Samples were electrophoresed through an 8% polyacrylamide-7
M urea sequencing gel. (C) Binding of CBF to the top and bottom strands of the SIVmacl42 enhancer. The SIVmacl42 enhancer probe
contains sequences from Sau3AI258 to Rsal71 (numbering relative to the transcriptional start site [7, 45]).

larger polypeptides upon addition of more protease inhibitors, suggest that proteolysis contributes to the multiplicity
of polypeptides in CBF preparations. Proteolysis may not be
the only contributing factor, however, and several distinct
core-binding proteins may be present in affinity-purified
CBF. Since inclusion of additional protease inhibitors dis-

Moloney MLV

7976
7948
CCAAACAGGATATCTGTGGTAAGCAGTTC
GGTTTGTCCTATAGACACCATTCGTCAAG

-171

SlVmacl 42

-1

42

AAAAGAAGGCTAGCCGCAAGAGGCCTTCTT
TTTTCTTCCGATCGGCGTTCTCCGGAAGAA
I
I

IgM
420
Ii
I
I
II
GGGAAAATAAAACCACTAGGTAAACTTGTAGCTGTGGTTTGAAGAAGTGGTTTTGAAACA
CCCTTTTATTTTGGTGATCCATTTGAACATCGACACCAAACTTCTTCACCAAAACTTTGT

TCRT
411

1

590

AGCAGTTAAACCACAGCCAGTTTTTGCTCGCTTTCGAAAGACCACAGCTATTAGACAGAA
TCGTCAATTTGGTGTCGGTCAAAAACGAGCGAAAGCTTTCTGGTGTCGATAATCTGTCTT
I
i

FIG. 10. Summary of CBF binding site analyses. Brackets indicate boundaries of protection by CBF from DNase I cleavage on the

Moloney MLV, immunoglobulin ,u-chain (IgM), TCR-y, and SIVmacl42 enhancers. The core sequences are indicated by heavy
horizontal bars. Guanine contacts in the Moloney MLV enhancer
core site are shown by open circles.

tributed CBF activity among more polypeptides, and our
ultimate goal is to purify sufficient quantities of one or more
polypeptides for microsequence analysis, we routinely include only PMSF during purification for CBF.
We have since obtained evidence that two of the CBF
polypeptides, a 21- and a 24-kDa protein, are very closely
related in primary structure. High-pressure liquid chromatography analysis of peptides obtained from tryptic digests
of the 21- and 24-kDa proteins yielded superimposable
peptide peaks, with the exception of one extra peptide peak
in the larger (24-kDa) protein (58).
Two other proteins that bind the core consensus sequence
in the Moloney virus enhancer have been purified to homogeneity: the CAAT/enhancer-binding protein (C/EBP) (29)
and activating protein 3 (AP-3) (41). For several reasons, we
believe that CBF is distinct from both C/EBP and AP-3.
First, the tissue distribution of CBF activity does not coincide with the tissue-specific expression of C/EBP. We detect
CBF activity in nuclear extracts prepared from calf thymus
and spleen but not from liver, kidney, lung, or heart, using
the WT Moloney enhancer core site as a probe (data not
shown). The tissue distribution of core-binding activity in
calf tissues is identical to that reported by Thornell et al. in
mouse tissues (55). Thus, the core-binding activity that we
and Thornell et al. detect appears to be confined to, or at
least enriched in, hematopoietic tissues. C/EBP, on the other
hand, was purified from rat liver and appears to be expressed
in cells that metabolize lipids and cholesterol-related compounds at rapid rates, including liver, fat, intestine, lung,
adrenal gland, and placenta, with no detectable expression in
the spleen (3). Thus, in three tissues, liver, lung, and spleen,
there is no overlap of C/EBP expression and CBF activity.
The other protein that was demonstrated to bind the Molo-
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ney MLV enhancer core site, AP-3, was purified from HeLa
cells. However, an extensive characterization of AP-3
expression has not been reported; thus, we cannot compare
its expression with that of CBF.
Another difference between CBF and both C/EBP and
AP-3 is that AP-3 and C/EBP bind the GT-I motif in the SV40
enhancer (29, 41), whereas CBF does not protect this
sequence from DNase I digestion. There is a 2-bp difference
between the Moloney MLV enhancer core site (CTGTGG
TAA) and the GT-1 motif (GTGTGGAAA); apparently one
or both of these substitutions are not compatible with CBF
binding. CBF also does not bind the homologous GT-IIC site
on the SV40 enhancer (CTGTGGAAT); thus, it is distinct
from the recently cloned transcriptional enhancer factor 1
(TEF-1) (64).
Finally, and most importantly, the sequence of a 26amino-acid tryptic peptide fragment of the 24-kDa CBF
polypeptide bears no significant homology to either C/EBP
or transcriptional enhancer factor 1 (58).
Since the Moloney MLV enhancer core site contributes
significantly to the thymic disease specificity of the Moloney
virus, it is quite likely that the proteins that bind the core site
also contribute to the transcriptional regulation of genes that
are expressed in T cells. As a first step in testing this
hypothesis, we have examined the enhancers from two
cellular genes specifically transcribed in lymphocytes for
CBF binding sites: the TCRy gene and the immunoglobulin
>i-chain gene. We have identified two bona fide binding sites
for CBF in the TCRy enhancer. These two sites are within a
196-bp fragment of the TCRy enhancer that comprise the
minimal enhancer fragment (52). Both of these sites were
protected from DNase I digestion by proteins in a 0.5 M KCl
eluate of a T-cell nuclear extract from a heparin-Sepharose
column (52). A third potential binding site for CBF in the
TCR-y enhancer is located 145 bp upstream of the two
confirmed CBF binding sites (52); however, binding to this
third site was not analyzed. A putative CBF binding site is
also present in the enhancer from the TCR5 gene, within a
250-bp region of the enhancer that contributes to transcription in T cells (44). Other investigators have similarly noted
core consensus sequences in the enhancers from other genes
specifically transcribed in T cells, including the TCRa,
TCRP, CD3R, and CD38 genes (52, 56).
CBF also binds three closely spaced core sites in the
immunoglobulin >L-chain enhancer. Although expression of
the completely rearranged immunoglobulin heavy-chain
gene (VH-DH-JH) is confined to B lymphocytes, transcription
from the unrearranged or partially rearranged (DH-JH) immunoglobulin heavy-chain locus also occurs in T cells (1,
32), and there is significant expression from introduced
immunoglobulin heavy-chain genes in the thymus of transgenic mice (22, 53). CBF may thus contribute to the transcription of both the TCRy and immunoglobulin >.-chain
gene in T cells, but proof of this awaits functional analyses.
We believe that CBF is analogous to the factors called
SEF1 by Thornell et al. (55) and S/A-CBF by Boral et al. (4).
SEF1 has recently been purified from calf thymus; affinitypurified preparations of SEF1 also contain multiple polypeptides with core-binding activity (54).
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